Gilead Sciences announced in a press release Wednesday that its COVID-19 drug remdesivir reduces hospitalizations by 87% in high-risk patients.
The study consisted of 562 patients who were randomly given either remdesivir to a placebo. The company said that it saw an 87% reduction in hospitalizations after day 28, according to the press release.
The trial was supposed to have over 1,000 subjects but the Gilead halted enrollment after other COVID-19 drugs became readily available.
The company also said that it saw an 81% reduction in medical visits due to COVID-19. One patient in the placebo group died, but it occurred after the day 28 cut-off for the trial.
“Antiviral medications provide maximal benefit when used early in the disease course. Last summer, data from clinical trials demonstrated the benefit of remdesivir in patients hospitalized with COVID-19, even not yet requiring oxygen,” Robert L. Gottlieb, cardiologist and principal investigator at the Baylor University Medical Center, said in the press release.
“These latest data show remdesivir’s potential to help high-risk patients recover before they get sicker and stay out of the hospital altogether,” Gottlieb said. “Remdesivir, also known as Veklury, is an effective antiviral for the treatment of hospitalized patients with COVID-19 and essential tool to help reduce disease progression.”
The Food and Drug Administration approved the antiviral drug on October 22, 2020, making it the first COVID-19 treatment authorized by the FDA.
The World Health Organization advised against the use of remdisivir for treating COVID-19, which was used to treat former President Trump when he was hospitalized with the virus in October.
Gilead continues to study the efficacy and safety of Veklury in hospitalized patient populations with ongoing unmet needs, such as patients with renal impairment, children and pregnant women, as well as through the support of a number of externally sponsored trials.
Gilead is also developing novel oral treatment options for non-hospitalized patients with COVID-19 and hopes to file investigational new drug applications (IND) with the Food and Drug Administration (FDA) by early next year.
- Florida Gov. DeSantis Expresses Concern About Biden Admin Cutting Supply Of Effective Antibody Treatments
- A Message From Florida’s New Public Health Chief: The State Will ‘Completely Reject Fear As A Way Of Making Policies In Public Health’
- Florida Man Steals Pickup Truck, Crashes, Pretends To Grill On Strangers Porch
- “Gut Him” Florida Woman Pulls Knife On Man After Dispute Over Her Passing Gas At Dollar General
- Florida Man And Woman, In Colorful Simpsons Shirts, Arrested On Multiple Drug Charges
- “Snickers Satisfies” Florida Man Arrested After Armed Robbery Of A Snickers Bar At Wawa
- Oops: Another Florida Pro-Mask Mandate Lib Caught Partying It Up Without A Mask
Support journalism by clicking here to our gofundme or sign up for our free newsletter by clicking here
Android Users, Click Here To Download The Free Press App And Never Miss A Story. It’s Free And Coming To Apple Users Soon.